I hold Avita and have seen how much the market slams companies when it looks like revenue growth is struggling to deal with cost escalation. And if the market sniffs a near term CR then the SP gets crushed. That said it wouldn't be hard to find some still a way off profitability and with revenue not much higher than Eye but much bigger market caps. At $51 million and around a PS ratio of 2 I can only call this undervalued. That only makes sense though if you're playing a longer game which is my situation.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-273
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.48M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 22.5¢ | $56.9K | 251.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 347271 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 92120 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |